Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines designed to target ear, nose, and throat (ENT) diseases, announced a $29.5 million Series B equity financing round led by Perceptive Advisors. New investors RA Capital Management, ArrowMark Partners, and Soleus Capital, as well as existing